Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Main Objective:
To evaluate progression-free survival in patients with unresectable renal cell carcinoma
(RCC) treated with a combination of gemcitabine, capecitabine, and sorafenib.